文章摘要

参考文献/References

［1］Haghighi K, Schmidt AG, Hoit BD,et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure［J］. J Biol Chem，2001,276(26):24145-24152.

［2］Pollesello P,Annila A.Structure of the 1-36 N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17［J］. Biophys J,2002, 83(1):484-490.

［3］Kirby TL, Karim CB, Thomas DD.Electron paramagnetic resonance reveals a large-scale conformational change in the cytoplasmic domain of phospholamban upon binding to the sarcoplasmic reticulum Ca-ATPase［J］. Biochemistry,2004, 43(19):5842-5852.

［4］Li J, Bigelow DJ, Squier TC.Conformational changes within the cytosolic portion of phospholamban upon release of CaATPase inhibition［J］. Biochemistry,2004,43(13):3870-3879.

［5］Schmidt AG, Zhai J, Carr AN,et al. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure［J］. Cardiovasc Res,2002,56(2):248-259.

［6］Maclennan DH, Kranias EG.Phospholamban: a crucial regulator of cardiac contractility［J］. Nat Rev Mol Cell Biol,2003,4(7):566-577.

［7］Song Q, Young KB, Chu G,et al. Overexpression of phospholamban in slow-twitch skeletal muscle is associated with depressed contractile function and muscle remodeling［J］. FASEB J,2004,18(9):974-976.

［8］Frank K, Kranias EG.Phospholamban and cardiac contractility［J］. Ann Med,2000, 32(8):572-578.

［9］Carr AN, Kranias EG.Thyroid hormone regulation of calcium cycling proteins［J］. Thyroid,2002,12(6):453-457.

［10］Braz JC, Gregory K, Pathak A,et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure［J］. Nat Med,2004,10(3):248-254.

［11］Asahi M, Otsu K, Nakayama H,et al. Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice［J］. Proc Natl Acad Sci USA,2004, 101(25):9199-9204.

［12］Schmitt JP,Kamisago M,Asahi M,et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban［J］. Science,2003,299(5611):1410-1413.

［13］Poller W, Fechner H, Kurreck J,et al. Nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases. Approaches and perspectives［J］. Z Kardiol,2004,93(3):171-193.

［14］Crystal RG.Pumping up the heart［J］. Gene Therapy,2003,10:2-3.

［15］del Monte F, Harding SE, Dec GW,et al. Targeting phospholamban by gene transfer in human heart failure［J］. Circulation,2002,105(8):904-907.

［16］Hoshijima M,Ikeda Y,Iwanaga Y,et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery［J］. Nat Med,2002,8(8):864-871.

［17］Iwanaga Y, Hoshijima M, Gu Y,et al.Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats［J］. J Clin Invest,2004,113(5):727-736.

［18］Chu D, Thistlethwaite PA, Sullivan CC,et al.Gene delivery to the mammalian heart using AAV vectors［J］. Methods Mol Biol,2004,246:213-224.

［19］Meyer M, Belke DD, Trost SU,et al.A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation［J］. FASEB J,2004，18：1312-1314.

［20］Schmidt AG, Edes I, Kranias EG.Phospholamban: a promising therapeutic target in heart failure?［J］. Cardiovasc Drugs Ther,2001,15(5):387-396.

［21］Janczewski AM, Zahid M, Lemster BH,et al.Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model［J］. Cardiovasc Res,2004,62(3):468-480.

我们的网站为什么显示成这样？

受磷蛋白与心力衰竭(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics